Cerenome (CNSY) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Cerenome (CNSY) over the past year, losing 42.7% versus a loss of 90.5%. Over five years, INAB leads with a -99.2% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($14.7 million vs $13.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | INAB |
|---|---|---|
| Share price | $1.94 | $1.36 |
| Market cap | $14.69M | $13.36M |
| 1-day change | +8.14% | -1.81% |
| YTD return | -85.96% | -41.03% |
| 1-year return | -90.45% | -42.74% |
| 5-year return | -99.73% | -99.23% |
| EPS (TTM) | $-3.36 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $2.73 |
| 52-week low | $1.49 | $0.88 |
| Distance from 52-week high | -89.81% | -50.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1333.59% | +416.61% |
| Average volume | 121.12K | 58.36K |
| Shares outstanding | 7.59M | 9.86M |
| Employees | 28 | 18 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed CNSY by 47.7 percentage points over the past year.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CNSY vs INAB FAQ
Which is bigger, Cerenome or IN8bio?
Cerenome (CNSY) is larger, with a market capitalization of $14.69M compared with $13.36M for IN8bio (INAB).
Which stock has performed better over the past year, CNSY or INAB?
INAB returned -42.74% over the past 12 months, compared with -90.45% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and IN8bio in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Cerenome and Biotechnology: Biological Products (No Diagnostic Substances) for IN8bio.